Beleave Inc.’s (CSE: BE) wholly-owned subsidiary, Bealeave Kannabis Corp., announced that it was granted a sales license by Health Canada under the ACMPR on Friday, April 13, 2018.
Beleave was granted a license to cultivate medical cannabis back in May 2017, and receiving a sales license for medical cannabis was a key component of the company’s strategy moving forward, which involves setting up distribution to North America and Europe.
Andrew Wnek, Beleave CEO, said “We are thrilled to have obtained our sales license from Health Canada. We have remained diligent and focused throughout the process. We are excited to be able to continue to move the company forward as a result of this news.”
Beleave has also granted certain board members the option to purchase stocks- 200,000 common shares at a price of $3.00/share, which expires on January 3, 2021.
Beleave’s 14,5000 sq. ft. facility is located in Hamilton, Ontario, and while the company is focused on cultivation, it is also expanding its facilities with a 66,000 sq. ft. greenhouse currently under construction and plans for a separate 200,000 sq. ft. facility.
Sources
Cision: Beleave receives sales license from Health Canada.
Investing News: Beleave- Canada’s newest medical marijuana licensed producer.